COALITION FOR A COMPETITIVE PHARMACEUTICAL MARKET

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2003–2010

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2010	—	2	1
2009	—	4	1
2008	—	4	1
2007	—	3	1
2006	—	2	1
2005	—	3	1
2004	—	3	1
2003	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FIERCE, ISAKOWITZ & BLALOCK	—	24

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	22
SENATE	22
White House Office	10
Food & Drug Administration (FDA)	9
Health & Human Services, Dept of (HHS)	9
Federal Trade Commission (FTC)	4
Medicare Payment Advisory Commission (MedPAC)	1
UNDETERMINED	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	23
Health Issues	Health Issues	9
Budget/Appropriations	Budget/Appropriations	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2010 · first_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: H.R. 3590: Patient Protection and Affordable Care Act H.R. 4872: Health Care and Education Affordability Reconciliation Act of 2010

Client expense: — · Firm income: $50,000

Matched citations: H.R. 3590

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: HR 3590

H.R. 3962110th Congress

Superfund Polluter Pays Act

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: HR 3962

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1427

Show 21 more cited filings

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: H.R. 1548

H.R. 3200111th Congress

America's Affordable Health Choices Act of 2009

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: HR 3200

S. 1679111th Congress

Affordable Health Choices Act

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: S. 1679

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: S726/H.R. 1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548: Pathway for Biosimilars Act S. 1679 Affordable Health Choices Act HR 3200 Americas Affordable Health Choices Act of 2009 HR 3962 Affordable Health Care for America Act HR 3590 Patient Protection and Affordable Care Act Americas Health Future Act of 2009 Biosimilar Reimbursement Utilization Equity Amendment Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: S726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · third_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: -S726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R.1548: Pathway for Biosimilars Act -S.1679 Affordable Health Choices Act Americas Health Future Act of 2009 -Biosimilar Reimbursement Utilization Equity Amendment -Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: H.R.1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · third_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: -S726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R.1548: Pathway for Biosimilars Act -S.1679 Affordable Health Choices Act Americas Health Future Act of 2009 -Biosimilar Reimbursement Utilization Equity Amendment -Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: H.R.1548

S. 1679111th Congress

Affordable Health Choices Act

2009 · third_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: -S726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R.1548: Pathway for Biosimilars Act -S.1679 Affordable Health Choices Act Americas Health Future Act of 2009 -Biosimilar Reimbursement Utilization Equity Amendment -Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: S.1679

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · third_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics: -S726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act -H.R.1548: Pathway for Biosimilars Act -S.1679 Affordable Health Choices Act Americas Health Future Act of 2009 -Biosimilar Reimbursement Utilization Equity Amendment -Limited Exception to Anti-Kickback Statute to Waive Co-payments For Generic Drugs

Client expense: — · Firm income: $50,000

Matched citations: S726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition Comprehensive Health Care Reform Senate Affordable Health Choices Act

Client expense: — · Firm income: $50,000

Matched citations: H.R.1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · second_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition Comprehensive Health Care Reform Senate Affordable Health Choices Act

Client expense: — · Firm income: $50,000

Matched citations: H.R.1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Generic Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition Comprehensive Health Care Reform Senate Affordable Health Choices Act

Client expense: — · Firm income: $50,000

Matched citations: S.726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · first_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition

Client expense: — · Firm income: $50,000

Matched citations: H.R.1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · first_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition

Client expense: — · Firm income: $50,000

Matched citations: H.R.1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · first_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.726/H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act H.R.1548: Pathway for Biosimilars Act Generic drug access and competition

Client expense: — · Firm income: $50,000

Matched citations: S.726

H.R. 1038110th Congress

Access to Life-Saving Medicine Act

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.623/H.R.1038: Access to Life Saving Medicines Act H.R.5629: Pathway for Biosimilars Act S.1695:, Biologics Price Competition and Innovation Act of 2007 State generic drug substitution laws

Client expense: — · Firm income: $50,000

Matched citations: H.R.1038

H.R. 4296110th Congress

Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

E- Prescribing -- H.R.4296/S.2408: Medicare Electontronic Medication and Safety Protection Act of 2007 As part of H.R. 6331: Medicare Improvements for Patients and Providers Act of 2008 H.R.4296/S.2408: Medicare Electronic and Safety Protection Act of 2007 (E-MEDS)

Client expense: — · Firm income: $50,000

Matched citations: H.R.4296

H.R. 5629110th Congress

Pathway for Biosimilars Act

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.623/H.R.1038: Access to Life Saving Medicines Act H.R.5629: Pathway for Biosimilars Act S.1695:, Biologics Price Competition and Innovation Act of 2007 State generic drug substitution laws

Client expense: — · Firm income: $50,000

Matched citations: H.R.5629

H.R. 6331110th Congress

Medicare Improvements for Patients and Providers Act of 2008

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

E- Prescribing -- H.R.4296/S.2408: Medicare Electontronic Medication and Safety Protection Act of 2007 As part of H.R. 6331: Medicare Improvements for Patients and Providers Act of 2008 H.R.4296/S.2408: Medicare Electronic and Safety Protection Act of 2007 (E-MEDS)

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6331

S. 1695110th Congress

Biologics Price Competition and Innovation Act of 2007

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.623/H.R.1038: Access to Life Saving Medicines Act H.R.5629: Pathway for Biosimilars Act S.1695:, Biologics Price Competition and Innovation Act of 2007 State generic drug substitution laws

Client expense: — · Firm income: $50,000

Matched citations: S.1695

S. 2408110th Congress

Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

E- Prescribing -- H.R.4296/S.2408: Medicare Electontronic Medication and Safety Protection Act of 2007 As part of H.R. 6331: Medicare Improvements for Patients and Providers Act of 2008 H.R.4296/S.2408: Medicare Electronic and Safety Protection Act of 2007 (E-MEDS)

Client expense: — · Firm income: $50,000

Matched citations: S.2408

S. 623110th Congress

Access to Life-Saving Medicine Act

2008 · fourth_quarter · Firm: FIERCE, ISAKOWITZ & BLALOCK

Open original LDA filing ↗

Cited source text and reported amounts

Biologics S.623/H.R.1038: Access to Life Saving Medicines Act H.R.5629: Pathway for Biosimilars Act S.1695:, Biologics Price Competition and Innovation Act of 2007 State generic drug substitution laws

Client expense: — · Firm income: $50,000

Matched citations: S.623

Source: Senate LDA

COALITION FOR A COMPETITIVE PHARMACEUTICAL MARKET — Lobbying Disclosure | Poliscope